Skip to main content
Print Save

Generic Silenor Availability

Last updated on Jan 11, 2023.

Silenor is a brand name of doxepin, approved by the FDA in the following formulation(s):

SILENOR (doxepin hydrochloride - tablet;oral)

  • Manufacturer: CURRAX
    Approval date: March 17, 2010
    Strength(s): EQ 3MG BASE [RLD] [AB], EQ 6MG BASE [RLD] [AB]

Has a generic version of Silenor been approved?

A generic version of Silenor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Silenor and have been approved by the FDA:

doxepin hydrochloride tablet;oral

  • Manufacturer: ACTAVIS ELIZABETH
    Approval date: July 26, 2013
    Strength(s): EQ 3MG BASE [AB], EQ 6MG BASE [AB]
  • Manufacturer: RK PHARMA
    Approval date: January 20, 2016
    Strength(s): EQ 3MG BASE [AB], EQ 6MG BASE [AB]
  • Manufacturer: STRIDES PHARMA
    Approval date: July 24, 2020
    Strength(s): EQ 3MG BASE [AB], EQ 6MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Silenor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods of using low-dose doxepin for the improvement of sleep
    Patent 10,238,620
    Issued: March 26, 2019
    Assignee(s): Pernix Sleep, Inc. ProCom One, Inc.

    Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).

    Patent expiration dates:

    • May 18, 2027
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Patent 10,548,871

    Patent expiration dates:

    • April 11, 2028
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Patent 10,653,660

    Patent expiration dates:

    • July 20, 2027
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Patent 10,653,662

    Patent expiration dates:

    • May 18, 2027
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Patent 11,096,920

    Patent expiration dates:

    • April 11, 2028
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Patent 11,110,074

    Patent expiration dates:

    • July 20, 2027
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Patent 11,234,954

    Patent expiration dates:

    • January 18, 2028
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Methods of improving the pharmacokinetics of doxepin
    Patent 7,915,307
    Issued: March 29, 2011
    Inventor(s): Casseday; Cara Baron & Ludington; Elizabeth & Skinner; Michael & Dubé; Susan & Rogowski; Roberta L. & Jochelson; Philip & Mansbach; Robert
    Assignee(s): Somaxon Pharmaceuticals, Inc.

    Methods of improving the pharmacokinetics of doxepin in a patient.

    Patent expiration dates:

    • August 24, 2027
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Methods of using low-dose doxepin for the improvement of sleep
    Patent 8,513,299
    Issued: August 20, 2013
    Assignee(s): Pernix Sleep, Inc. Procom One, Inc.

    Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).

    Patent expiration dates:

    • September 7, 2030
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Methods of using low-dose doxepin for the improvement of sleep
    Patent 9,107,898
    Issued: August 18, 2015
    Assignee(s): Pernix Sleep, Inc.

    Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).

    Patent expiration dates:

    • May 1, 2028
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Methods of using low-dose doxepin for the improvement of sleep
    Patent 9,486,437
    Issued: November 8, 2016
    Assignee(s): Pernix Sleep, Inc. ProCom One, Inc.

    Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).

    Patent expiration dates:

    • May 18, 2027
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Low-dose doxepin formulations and methods of making and using the same
    Patent 9,532,971
    Issued: January 3, 2017
    Assignee(s): Pernix Sleep, Inc.

    The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.

    Patent expiration dates:

    • June 1, 2029
      ✓ 
      Drug product
  • Methods of improving the pharmacokinetics of doxepin
    Patent 9,572,814
    Issued: February 21, 2017
    Assignee(s): Pernix Sleep, Inc.

    Methods of improving the pharmacokinetics of doxepin in a patient.

    Patent expiration dates:

    • July 20, 2027
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Methods of using low-dose doxepin for the improvement of sleep
    Patent 9,861,607
    Issued: January 9, 2018
    Assignee(s): Procom One, Inc. Pernix Sleep, Inc.

    Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).

    Patent expiration dates:

    • May 18, 2027
      ✓ 
      Patent use: TREATMENT OF INSOMNIA
  • Low-dose doxepin formulations and methods of making and using the same
    Patent 9,907,780
    Issued: March 6, 2018
    Assignee(s): Pernix Sleep, Inc.

    The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep.

    Patent expiration dates:

    • April 11, 2028
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer